Prior transarterial chemoembolization and outcomes after palliative radiotherapy in advanced hepatocellular carcinoma: a retrospective cohort study

Abstract Advanced hepatocellular carcinoma (HCC) is increasingly managed with combinations of locoregional therapies and systemic immunotherapy or targeted therapy, yet the optimal sequencing of these modalities remains undefined. This retrospective cohort study evaluated the impact of prior transarterial chemoembolization (TACE) on outcomes after palliative radiotherapy (RT) and the contribution of post-RT systemic immunotherapy and targeted therapy to survival in advanced HCC. A total of 82 patients with TNM stage III/IV HCC receiving palliative RT (2022–2025) were categorized by prior TACE exposure (Prior-TACE, n=37; Non-prior TACE, n=45). Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier estimates and multivariate Cox models. In unadjusted analysis, the Non-prior TACE group demonstrated superior PFS (HR 0.47, 95% CI: 0.28–0.78, p=0.0037) and OS (HR 0.53, 95% CI: 0.28–0.98, p=0.0459). After multivariate adjustment, absence of prior TACE remained independently associated with improved PFS (adjusted HR=0.56, 95% CI: 0.33–0.95, p=0.032) but not OS (adjusted HR=0.73, 95% CI: 0.36–1.48, p=0.378). Independent predictors of OS included Child-Pugh class B (HR=3.22, p=0.039), TNM stage IV (HR=2.60, p=0.027) and receipt of post-RT targeted therapy (HR=0.25, p=0.003). Safety profiles were comparable between groups. In this real-world cohort, survival after palliative RT was predominantly determined by baseline liver function, tumor stage and incorporation of subsequent targeted therapy, while prior TACE independently influenced PFS. These findings inform the rational integration of locoregional therapy with systemic therapy and warrant prospective validation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11305805/v1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Prior transarterial chemoembolization and outcomes after palliative radiotherapy in advanced hepatocellular carcinoma: a retrospective cohort study

Jianxin Chen, Jinli Zhang, Junhui Wang
Research Square
Hepatocellular Carcinoma Treatment and Prognosis
preprint

Prior transarterial chemoembolization and outcomes after palliative radiotherapy in advanced hepatocellular carcinoma: a retrospective cohort study

Jianxin Chen, Jinli Zhang, Junhui Wang
preprint en

Abstract

Abstract Advanced hepatocellular carcinoma (HCC) is increasingly managed with combinations of locoregional therapies and systemic immunotherapy or targeted therapy, yet the optimal sequencing of these modalities remains undefined. This retrospective cohort study evaluated the impact of prior transarterial chemoembolization (TACE) on outcomes after palliative radiotherapy (RT) and the contribution of post-RT systemic immunotherapy and targeted therapy to survival in advanced HCC. A total of 82 patients with TNM stage III/IV HCC receiving palliative RT (2022–2025) were categorized by prior TACE exposure (Prior-TACE, n=37; Non-prior TACE, n=45). Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier estimates and multivariate Cox models. In unadjusted analysis, the Non-prior TACE group demonstrated superior PFS (HR 0.47, 95% CI: 0.28–0.78, p=0.0037) and OS (HR 0.53, 95% CI: 0.28–0.98, p=0.0459). After multivariate adjustment, absence of prior TACE remained independently associated with improved PFS (adjusted HR=0.56, 95% CI: 0.33–0.95, p=0.032) but not OS (adjusted HR=0.73, 95% CI: 0.36–1.48, p=0.378). Independent predictors of OS included Child-Pugh class B (HR=3.22, p=0.039), TNM stage IV (HR=2.60, p=0.027) and receipt of post-RT targeted therapy (HR=0.25, p=0.003). Safety profiles were comparable between groups. In this real-world cohort, survival after palliative RT was predominantly determined by baseline liver function, tumor stage and incorporation of subsequent targeted therapy, while prior TACE independently influenced PFS. These findings inform the rational integration of locoregional therapy with systemic therapy and warrant prospective validation.

Research Square
Wenzhou Medical University (CN), Quzhou City People's Hospital (CN)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon